Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests. Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD).
Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease.
KEY BENEFITS
This report offers the following benefits in particular:
KEY MARKET SEGMENTS
Ebola therapeutics and vaccines market is segmented on the basis of geography.
CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segment
1.3 Key Audiences
1.4 Research Methodology
1.4.1 Primary Research
1.4.2 Secondary Research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top factor impacting the market growth
3.2.2 Top investment pockets
3.3 Key market player positioning
3.4 Ebola Virus Key Facts
3.4.1 Transmission of Ebola
3.4.2 Signs and symptoms of ebola
3.4.3 Diagnosis of ebola
3.4.4 Vaccine or treatment available for ebola
3.5 Amend for anti-Ebola disease drugs in United States
3.6 Guidance on Air Medical Transport for Patients with Ebola Virus Disease
3.7 “Fast Track” designation to Anti-E bola drugs research from the U.S. government
3.8 ZMMP Drug: An Orphan solution for E-bola viral disease
3.8.1 ZMAPP is not ready for prime time
3.8.1.1 Orphan Drugs for Orphan Diseases
3.9 Ethical Dilemmas from therapeutics
3.10 Tekmira Pharma received boost to ebola R&D through FDA fundings
3.11 Clinical Trials
3.12 Market Dynamics
3.12.1 Drivers
3.12.1.1 Prevalent cases and unpredictable nature of disease
3.12.1.2 Increased rate of migration from developing countries
3.12.1.3 Lack of relevant medication
3.12.2 Restraints
3.12.2.1 High initial investment for R&D
3.12.2.2 Obstractive ethical considerations
3.12.3 Opportunities
3.12.3.1 Development of economic vaccines and drugs
3.12.3.2 Gaining competitive edge in developing economies
CHAPTER 4 FORECASTE SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-2020, ($MILLION)
4.1 Moderate growth scenario
4.2 Rapid growth scenario
4.3 Diminishing growth scenario
CHAPTER 5 GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF E-BOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY, 2013 – 2020
5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 LAMEA
CHAPTER 6 COMPANY PROFILES
6.1 Tekmira Pharmaceuticals
6.1.1 Overview
6.1.2 Company snapshot
6.1.3 Financial performance
6.1.4 Strategic moves and developments
6.1.5 SWOT analysis
6.2 BioCryst Pharmaceutical Inc.
6.2.1 Overview
6.2.2 Company snapshot of BioCryst Pharmaceutical Inc.
6.2.3 Financial performance
6.2.4 Strategic moves and developments
6.2.5 SWOT analysis
6.3 Serepata Therapeutics
6.3.1 Overview
6.3.2 Company snapshot
6.3.3 Strategic moves and developments
6.3.4 SWOT analysis
6.4 NewLink Genetics Corp.
6.4.1 Overview
6.4.2 Company snapshot
6.4.3 Financial performance
6.4.4 Strategic moves and developments
6.4.5 SWOT analysis
6.5 Mapp Biopharmaceutical
6.5.1 Overview
6.5.2 Company snapshot
6.5.3 Strategic moves and developments
6.5.4 SWOT analysis of Mapp Biopharmaceutical
LIST OF FIGURES
FIG. 1 TOP IMPACTING FACTORS OF EBOLA VIRAL DISEASE DRUGS (2013-2020)
FIG. 2 TOP INVESTMENT POCKETS
FIG. 3 KEY MARKET PLAYER POSITIONING OF EBOLA THERAPEUTICS
FIG. 4 MILESTONE OF E-BOLA DISEASE PREVALENCE BY GEOGRAPHIES
FIG. 5 SURGED EBOLA INCIDENCES IN WEST AFRICA (2014)
FIG. 6 TEKMIRA’S NET REVENUE FROM RESEARCH COLLABORATIONS AND CONTRACTS (2013)
FIG. 7 SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS
FIG. 8 R&D EXPENSES OF BIOCRYST PHARMACEUTICAL INC. (2013)
FIG. 9 SWOT ANALYSIS OF BIOCRYST PHARMACEUTICAL INC.
FIG. 10 SWOT ANALYSIS OF SEREPATA THERAPEUTICS
FIG. 11 RESEARCH AND DEVELOPMENT EXPENSES BY PRODUCTS (2013)
FIG. 12 SWOT ANALYSIS OF NEWLINK GENETICS CORP.
FIG. 13 SWOT ANALYSIS OF MAPP BIOPHARMACEUTICAL
LIST OF TABLES
TABLE 1 CHRONOLOGY OF E-BOLA VIRUS INCIDENCE
TABLE 2 CLINICAL TRIAL NO I
TABLE 3 CLINICAL TRIAL NO II
TABLE 4 CLINICAL TRIAL NO III
TABLE 5 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 6 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 7 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 8 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 9 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 10 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 11 GLOBAL EVD POTENTIAL VACCINES MARKET BY GEOGRAPHY, 2015-2020, (THOUSAND UNITS)
TABLE 14 GLOBAL EVD VACCINES DEMAND BY GEOGRAPHY, 2015-2020, (UNITS IN THOUSAND)
TABLE 15 COMPANY SNAPSHOT OF TEKMIRA PHARMACEUTICALS
TABLE 16 COMPANY SNAPSHOT OF BIOCRYST PHARMACEUTICAL INC.
TABLE 17 COMPANY SNAPSHOT OF SEREPATA THERAPEUTICS
TABLE 18 COMPANY SNAPSHOT OF NEWLINK GENETICS CORP.
TABLE 19 COMPANY SNAPSHOT OF MAPP BIOPHARMACEUTICAL
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
